High versus low dose losartan and serum potassium: an analysis from HEAAL.
Fiche publication
Date publication
octobre 2022
Journal
Journal of cardiac failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Konstam M, Rossignol P, Kiernan MS, Zannad F
Lien Pubmed
Résumé
Patients with HF experience frequent alterations of serum potassium. Despite the high risk of events associated with hypokalemia, hyperkalemia is feared by clinicians and often leads to interruption or discontinuation of RAAS inhibitors. Data on serum potassium of patients treated with different doses of RAAS inhibitors are scarce.
Mots clés
Potassium, heart failure treatment, losartan
Référence
J Card Fail. 2022 10 13;: